Native Kidney Cancer Is Prevalent Among Kidney Transplant Recipients – Oncology Nurse Advisor
Researchers investigated the prevalence of different cancers and other clinical outcomes in kidney transplant recipients.
Related Articles
ADCs and ICIs Have Boosted Survival in Metastatic Urothelial Cancer – Oncology Nurse Advisor
US patients with metastatic urothelial cancer have seen improvements in survival since ICIs and ADCs have entered the market, data suggest.
ADCs and ICIs Have Boosted Survival in Metastatic Urothelial Cancer – Oncology Nurse Advisor
US patients with metastatic urothelial cancer have seen improvements in survival since ICIs and ADCs have entered the market, data suggest.
MATTERHORN “Supports Global Adoption” of Durvalumab-FLOT for Gastric/GEJ Cancer – Oncology Nurse Advisor
“MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena…
Few Cancer Survivors With Alcohol Use Disorder Receive Timely Treatment for It – Oncology Nurse Advisor
Future research should explore barriers to treatment for alcohol use disorder, researchers say.
Microbiome Diversity Linked to Outcomes in Pediatric Diffuse Midline Gliomas – Oncology Nurse Advisor
New research suggests that pediatric patients with diffuse midline gliomas may have better outcomes if they have a more diverse gut microbiome.
Study Suggests a Less Stringent Approach to Hematopoietic Cell Donor Selection – Oncology Nurse Advisor
Recent evidence demonstrates that advances in GVHD prophylaxis may allow for use of broader selection criteria for hematopoietic cell transplantation donors.
Lurbinectedin-Atezolizumab Maintenance: A New Standard for ES-SCLC? – Oncology Nurse Advisor
“e believe that there is potential for lurbinectedin plus atezo to be a standard of care in this setting,” said Luis G. Paz-Ares, MD, PhD.
Postoperative ctDNA Results Predict RFS, OS in NSCLC – Oncology Nurse Advisor
Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.
Polatuzumab Vedotin Improves PFS, OS in Rel/Ref DLBCL – Oncology Nurse Advisor
Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.
Increasing HCC Mortality Rates in US Rural Populations May Be Driven by HCV – Oncology Nurse Advisor
US researchers analyzed national death certificate data to compare trends in hepatocellular carcinoma (HCC)-related mortality and underlying etiologies of chronic liver disease linked to HCC-related…